ReviewStem cells translational medicine2026
Genomic stability of human pluripotent stem cells: advances in research and screening criteria.
Review in Stem cells translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Genetic and acquired genomic abnormalities pose substantial risks to human pluripotent stem cells (hPSCs), presenting a critical challenge to their safe use in both research and clinical applications. Although hPSCs possess intrinsic regulatory mechanisms that support genomic stability, diverse culture conditions and extended in vitro expansion inevitably give rise to chromosomal and subchromosomal abnormalities. Genomic adaptation during long-term culture, therefore, remains an unavoidable phenomenon. This review synthesizes recent advances in understanding the determinants of hPSC genomic stability and highlights strategies to preserve stem cell quality. Furthermore, it summarizes current screening criteria for defining safe stem cell lines, providing a valuable reference for their translational use. Together, these insights lay the groundwork for improving culture systems, refining monitoring techniques, and guiding the development of safer and more reliable stem cell-based applications in regenerative medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.